Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 75.48

+1.4%

Nov 14 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (433)	12/6/2003 6:11:40 PM
From: Jibacoa	Read Replies (1) of 3722

CELG Which has had a 100% performance since January, is also expected to benefit from the data it will be presenting this week at ASH. CELG will present data from its on-going trials of ACTIMID in multiple myeloma,which recently is been evaluated as a single agent therapy for relapsed/refractory myeloma. Besides Actimid (CC-4047),CELG will also present some data on its Revimid (CC-5013)which is on trials for cancer and inflammatory diseases, including multiple myeloma, metastatic melanoma, myelodysplastic syndromes,and glioblastoma. biz.yahoo.com siliconinvestor.com Since late February, CELG has remained on an UPTREND with the averages of the right sequence.<g> bigcharts.marketwatch.com Bernard

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next